Early Manifest Glaucoma Trial (EMGT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00000132|
Recruitment Status : Unknown
Verified October 2001 by National Eye Institute (NEI).
Recruitment status was: Active, not recruiting
First Posted : September 24, 1999
Last Update Posted : June 24, 2005
The primary purpose is to compare the effect of immediate therapy to lower the intraocular pressure (IOP) versus late or no treatment on the progression of newly detected open-angle glaucoma, as measured by increasing visual field loss and/or optic disc changes.
The secondary purposes are to determine the extent of IOP reduction attained by treatment, to explore factors that may influence glaucoma progression, and to describe the natural history of newly detected glaucoma.
|Condition or disease||Intervention/treatment||Phase|
|Open-Angle Glaucoma||Drug: Betaxolol Procedure: Argon Laser Trabeculoplasty||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Study Start Date :||October 1992|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000132
|Department of Ophthalmology, Helsingborg Hospital|
|Department of Ophthalmology, Malmo University Hospital, University of Lund|